COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system

被引:313
作者
Bech-Otschir, D
Kraft, R
Huang, XH
Henklein, P
Kapelari, B
Pollmann, C
Dubiel, W
机构
[1] Humboldt Univ, Fac Med Charite, Dept Surg, Div Mol Biol, D-10117 Berlin, Germany
[2] Humboldt Univ, Fac Med Charite, Inst Biochem, D-10117 Berlin, Germany
[3] Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany
[4] Max Planck Inst Biochem, Dept Biol Struct, D-82152 Martinsried, Germany
关键词
COP9; signalosome; Jab1; Mdm2; proteasome; ubiquitin;
D O I
10.1093/emboj/20.7.1630
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In higher eukaryotic cells, the p53 protein is degraded by the ubiquitin-26S proteasome system mediated by Mdm2 or the human papilloma virus E6 protein. Here we show that COP9 signalosome (CSN)-specific phosphorylation targets human p53 to ubiquitin-26S proteasome-dependent degradation. As visualized by electron microscopy, p53 binds with high affinity to the native CSN complex. p53 interacts via its N-terminus with CSN subunit 5/Jab1 as shown by far-western and pull-down assays. The CSN-specific phosphorylation sites were mapped to the core domain of p53 including Thr155. A phosphorylated peptide, Delta p53(145-164), specifically inhibits CSN-mediated phosphorylation and p53 degradation. Curcumin, a CSN kinase inhibitor, blocks E6-dependent p53 degradation in reticulocyte lysates. Mutation of Thr155 to valine is sufficient to stabilize p53 against E6-dependent degradation in reticulocyte lysates and to reduce binding to Mdm2. The p53T155V mutant accumulates in both HeLa and HL 60 cells and exhibits a mutant (PAb 240+) conformation. It induces the cyclin-dependent inhibitor p21, In HeLa and MCF-7 cells, inhibition of CSN kinase by curcumin or Delta p53(145-164) results in accumulation of endogenous p53.
引用
收藏
页码:1630 / 1639
页数:10
相关论文
共 44 条
  • [1] Curcumin is an in vivo inhibitor of angiogenesis
    Arbiser, JL
    Klauber, N
    Rohan, R
    van Leeuwen, R
    Huang, MT
    Fisher, C
    Flynn, E
    Byers, HR
    [J]. MOLECULAR MEDICINE, 1998, 4 (06) : 376 - 383
  • [2] Enhanced phosphorylation of p53 by ATN in response to DNA damage
    Banin, S
    Moyal, L
    Shieh, SY
    Taya, Y
    Anderson, CW
    Chessa, L
    Smorodinsky, NI
    Prives, C
    Reiss, Y
    Shiloh, Y
    Ziv, Y
    [J]. SCIENCE, 1998, 281 (5383) : 1674 - 1677
  • [3] Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells
    BeerRomero, P
    Glass, S
    Rolfe, M
    [J]. ONCOGENE, 1997, 14 (05) : 595 - 602
  • [4] Integrin LFA-1 interacts with the transcriptional co-activator JAB1 to modulate AP-1 activity
    Bianchi, E
    Denti, S
    Granata, A
    Bossi, G
    Geginat, J
    Villa, A
    Rogge, L
    Pardi, R
    [J]. NATURE, 2000, 404 (6778) : 617 - +
  • [5] Cell cycle - Piecing together the p53 puzzle
    Carr, AM
    [J]. SCIENCE, 2000, 287 (5459) : 1765 - 1766
  • [6] JAB1 interacts with both the progesterone receptor and SRC-1
    Chauchereau, A
    Georgiakaki, M
    Perrin-Wolff, M
    Milgrom, E
    Loosfelt, H
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) : 8540 - 8548
  • [7] Chehab NH, 2000, GENE DEV, V14, P278
  • [8] CRYSTAL-STRUCTURE OF A P53 TUMOR-SUPPRESSOR DNA COMPLEX - UNDERSTANDING TUMORIGENIC MUTATIONS
    CHO, YJ
    GORINA, S
    JEFFREY, PD
    PAVLETICH, NP
    [J]. SCIENCE, 1994, 265 (5170) : 346 - 355
  • [9] A new group of conserved coactivators that increase the specificity of AP-1 transcription factors
    Claret, FX
    Hibi, M
    Dhut, S
    Toda, T
    Karin, M
    [J]. NATURE, 1996, 383 (6599) : 453 - 457
  • [10] The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators
    Dechend, R
    Hirano, F
    Lehmann, K
    Heissmeyer, V
    Ansieau, S
    Wulczyn, FG
    Scheidereit, C
    Leutz, A
    [J]. ONCOGENE, 1999, 18 (22) : 3316 - 3323